margetuximab + pembrolizumab

Margetuximab + pembrolizumab is an investigational combination therapy consisting of **margetuximab**, an Fc-engineered monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), and **pembrolizumab**, a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Margetuximab has been designed to enhance innate immune response compared to trastuzumab, while pembrolizumab acts as an immune checkpoint inhibitor to potentiate T-cell activation. This combination was evaluated for the treatment of **HER2-positive, relapsed/refractory advanced gastroesophageal junction or gastric cancer**, where it demonstrated acceptable safety and an objective response rate (ORR) of approximately 18–19% in an all-comers population, with higher responses in biomarker-selected patients. The combination exemplifies a **chemo-free immunotherapy strategy** targeting both tumor cell surface antigens (HER2) and immune checkpoints (PD-1)[1][3][5][6].

Other names

margetuximab and pembrolizumab combination